Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0FJ3P
|
||||
| Former ID |
DIB008409
|
||||
| Drug Name |
GW-2592X
|
||||
| Synonyms |
Azepanone inhibitors, GlaxoSmithKline; Cathepsin K inhibitors (bone disorder); Cathepsin K inhibitors, SmithKline Beecham; GW-2592X; GW-2637X; GW-2934X; GW-9696X; SB-237632; SB-244875; SB-267320; SB-271194; SB-327537; SB-331750; SB-357114; SB-432238; SB-553484; Cathepsin K inhibitors (bone disorder), GlaxoSmithKline
|
||||
| Indication | Bone disease [ICD10:M00-M99] | Investigative | [1] | ||
| Company |
SmithKline Beecham Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
CC(C)([C@@H](Cc1[nH]c(cn1)c1ccc(C(F)(F)F)cc1)OC(=O)N[C@<br />H](C(=O)C(=O)Nc1[nH]ncc1)CCCC)C
|
||||
| Target and Pathway | |||||
| Target(s) | Cathepsin K | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Lysosome | ||||
| Osteoclast differentiation | |||||
| Toll-like receptor signaling pathway | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| RANKL Signaling Pathway | |||||
| IL2 Signaling Pathway | |||||
| Reactome | Collagen degradation | ||||
| Degradation of the extracellular matrix | |||||
| Activation of Matrix Metalloproteinases | |||||
| Trafficking and processing of endosomal TLR | |||||
| MHC class II antigen presentation | |||||
| WikiPathways | RANKL/RANK Signaling Pathway | ||||
| Osteoclast Signaling | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2350). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.